Impact of SGLT2 Inhibitors in Heart Transplant Recipients

PHASE2Enrolling by invitationINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

November 20, 2023

Primary Completion Date

February 1, 2025

Study Completion Date

August 1, 2025

Conditions
Transplant; Failure, HeartCardiac Allograft VasculopathyRejection Heart Transplant
Interventions
DRUG

SGLT2i

A randomized clinical trial of superiority with active control (2 arms), with central randomization to evaluate the efficacy and safety of adding dapagliflozin or empagliflozin 10 mg once daily to post-TxC routine compared with no intervention for 6-8 months.

Trial Locations (1)

Unknown

Messejana Hospital, Fortaleza

All Listed Sponsors
collaborator

Hospital de Messejana

UNKNOWN

lead

Universidade Federal do Ceara

OTHER